| Project/Area Number |
22790173
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Meiji Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | miRNA / バイオマーカー / 肺がん / 薬剤耐性 / ゲフィチニブ / 薬剤反応性 / マイクロアレイ / 化学療法 |
|---|
| Research Abstract |
Gefitinib has been used for treatment of non-small cell lung cancer. The EGFR gene mutation correlates with clinical response to Gefitinib. However, some patients are resistant to Gefitinib despite the existence of mutated EGFR gene. This resistance is a major problem in patients with NSCLC. Sensitive biomarker is required for effective therapy with chemotherapeutic drugs. Recently, circulating tumor cell and microRNA(miRNA) are focused on as biomarkers for cancer diagnosis.
In this study, we utilized miRNA array and real-time PCR to show that some miRNAs are significantly up-regulated in Gefitinib resistant lung cancer cell lines. Using the miRNA specific inhibitors, we identified ErbB family molecules are as a target gene of these miRNAs.
|
